Background: To evaluate the efficacy of topical antiinflammatory agent (amlexanox 5%), along with topical antiseptic, analgesic, and anesthetic agent (benzalkonium chloride 0.01%, choline salicylate 8.7% and lidocaine hydrochloride 2%), in promoting ulcer healing, decreasing ulcer size, erythema, pain and recurrence in minor RAS. Materials & Methods: A randomized control trial was conducted on 100 patients of RAS who fulfilled the inclusion criteria. The number, size, erythema and pain with the ulcer were recorded. Visual analogue scale (VAS) and erythema scale were used to record pain and erythema. 50 patients comprising the study group received anti inflammatory paste (amlexanox 5%) applied four times daily and the control group of 50 patients received topical antiseptic, analgesic, and anesthetic agent (benzalkonium chloride 0.01%, choline salicylate 8.7% and lidocaine hydrochloride 2%) paste, patients were evaluated after 3rd, 6th, 9th and on 30th, 60th day for recurrence. Results: The study group had reduction in ulcer number, size; erythema, pain and frequency of ulcers during follow up. The healing period and recurrence of ulceration reduced in both the groups but the study group had significant reduction in 30th and 60th day follow up for recurrence of ulcers. Conclusion: Amlexanox 5% can reduce the frequency, duration and symptoms associated with the aphthous ulcers with no sideeffects attributed to the drug.
Introduction
Recurrent aphthous ulceration or recurrent aphthous stomatitis is the most common oral mucosal disease known to human beings and has ever since been the subject of considerable clinical and research attention, because of its multiple etiologies and various treatment modalities with no much of cure. The term "aphthae" refers to presence of an otherwise undefined ulcer. Hippocrates (460-370BC) was the first to use the term aphthai, he used this term to describe all disorders affecting the mouth. However, the first valid clinical description of RAS is credited to Von Mikulicz and Kummel (1888). The prevalence of RAS in general population is of the order of 5 to 25%, 1 effecting men and women of all ages, races, and geographic regions. 2 The disease is characterized by recurrent, painful ulcers that are small, round to ovoid, affecting non-keratinized oral mucosa such as buccal mucosa, lateral and ventral aspects of the tongue, floor of the mouth and soft palatal and oropharyngeal mucosa with a crateriform based covered by a grey white pseudomembrane and surrounded by a distinct erythematous halo. 3 Many investigators have classified RAS into three subtypes: minor aphthous ulcers, major aphthous ulcers and herpetiform ulcer. [4] [5] [6] [7] [8] [9] Minor RAU is the most common manifestation of the disorder, occurring in 75-80% of patient with RAU. This is characterized by shallow round or oval lesions of < 10 mm in diameter. [4] [5] [6] [7] [8] [9] Major RAU is a more severe from, affecting approximately 10% of patients with RAU. Lesions are generally deeper than those observed in minor RAU, often exceed 10 mm in diameter and generally take several weeks to heal with scar. [4] [5] [6] [7] [8] [9] Herpetiform ulcers are multiple clusters of ulcers and are between 2-3 mm in diameter, approximately 10% of patients presenting with RAU have the herpetiform manifestation. [4] [5] [6] [7] [8] [9] RAU can also be classified as simple aphthosis or complex aphthosis. The Simple manifestation is characterized by short -lived episodes involving a few lesions that heal quickly with minimal pain. Conver-sely, complex aphthosis is a more disabling state, char-acterized by numerous and large lesions, continued ulceration and marked pain. Furthermore, lesions may occur in the genital or perianal regions. 10, 11 Despite extensive investigations, studies have failed to find the exact etiology and pathogenesis of this condition. Hereditary, hematinic deficiencies, immune dysregulation, some food, drugs, psychic stress, local trauma, hormonal disturbances, infections, cessation of smoking, poor oral hygiene are proposed factors. 1, 3 Since the etiology is unknown, the diagnosis is entirely based on history and clinical criteria and no laboratory procedures exist to confirm the diagnosis. Although a variety of treatment modalities have been suggested to eliminate or reduce the duration of recurrences, their clinical value remains unproven and can be controversial, most common treatment involves the use of topical agents to provide symptomatic relief, and these include antibiotics, analgesics, non-steroidal antiinflammatory drugs, corticosteroids and immunomodulators. 12, 13 The purpose of this study is to evaluate the efficacy of amlexanox 5% in promoting ulcer healing, decreasing ulcer number, size, erythema, resolving pain and recurrence associated with RAS when applied topically. Compared with topical antiseptic, analgesic, and anesthetic agent (benzalkonium chloride 0.01%, choline salicylate 8.7% and lidocaine hydrochloride 2% Materials and Methods A total of 100 patients with minor RAS were volunteered in the study. These patients were randomly selected from different private dental clinic of different parts of Karnataka.
The following criteria were utilized to select patient: 
Results
In the study group, out of 50 patients, 41 were male and 9 were females (male: female ratio of 4.5:1) their age range from 14 years -36 years (mean 25 years). Of the 50 patient in comparison group, 32 were males and 18 were females (male: female ratio of 1.7:1) their age range from 18 years -36 years (mean 27 years). At the time of presentation, the number of the ulcers in each patient (Table 1 ) and the sites of the ulcers were recorded ( 1st day 3rd day 6th day 9th day groups. However when overall comparison of the score was made, the study group had lower pain scores then the control group (Table 4 
Discussion
Recurrent aphthous stomatitis is one of the most common oral ailments. The patient of RAS presents with painful, recurring ulcers of the oral cavity. Diagnosis of RAS rests on features like: a history of recurrent ulcers since childhood or adolescence and presence of typical multiple round or ovoid ulcers on examination. groups. However when overall comparison of the score was made, the study group had lower pain scores then the control group (Table 4 and 6) (Graph 4). Recurrence was calculated between two groups on 30 th and 60 th day, study group showed 18% recurrence in 30th day and 14% recurrence in 60 th day and control group showed 26% recurrence in 30th day and 28% recurrence in 60 th day (Table 8 ) (Graph 5).
Recurrent aphthous stomatitis is one of the most common oral ailments. The patient of RAS presents with painful, recurring ulcers of the oral cavity. Diagnosis of RAS rests on features like: a history of recurrent ulcers since childhood or adolescence and presence of typical multiple round or ovoid ulcers on examination. groups. However when overall comparison of the score was made, the study group had lower pain scores then the control group (Table 4 Role of humoral immunity in RAS too has been suggested by some authors. In a study on Spanish patient the IgG 2 subclass was lowered. 19 Hence treatments such as corticosteroids and Immunosuppressive agents like cyclosporine, azathioprine, thalidomide are also used but can produce a number of serious side effects. 1 Amlexanox 5% (Lexanox), a topical anti-inflammatory agent has recently been found to have significant role in management of minor aphthous ulcers. 13 Amlexanox (C 16 H 14 N 2 O 4 ) is a topical anti-inflammatory, anti-allergic drug. Amlexanox potentialy inhibit the formation and release of histamine and luekotrines from mast cells, neutrophils, and mononuclear cells. Histamine and leukotrines are vasoactive inflammatory mediators which can only increase the permeability of vessels and therefore cause swelling of the involved tissues, but also contribute to inflammation by affecting the functions of other leukocytes in the involved area. 20, 21 In present study patient on amlexanox 5% reported reduced number of ulcers on comparison to pre treatment period and in control group, though the number reduced was not of that significance indicating greater ulcer free days in study group. Size and erythema also reduce in both the groups. On comparision between the groups the size and erythema was lower in the study group than the control group. This reduction was not significant on the 1 day of ulcer size and 1 st , 3 rd day of erythema which showed near approximation with previous studies done by Jie Liu et al and Greer et al. 20, 22 Signs and symptoms in both the groups had reduced which was noted by reduction in the VAS scores throughout treatment and post-treatment period. This indicates that both drugs could bring about reduction in the pain. However, on comparing between two groups, the patients on amlexanox 5% had a significant lower VAS values than the control group. Which showed approximation with previous studies done by Atul Khandwala et al. 12, 13 Calculating recurrence, study group showed 18% recurrence in 30 th day and 14% recurrence in 60 th day follow-up and control group showed 26% recurrence in 30 th day and 28% recurrence in 60 th day follow-up showing tremendous reduction in recurrence of ulcers in the study group then control group. No adverse effects were reported in the present study. Corroborating with the study of Atul Khandwala wher in no adverse reactions were reported.
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Conclusion
Anti-inflammatory oral paste (Amlexanox 5%) when used topically can bring considerable improvement in signs and symptoms associated with RAS. This study has shown reduction in number, size, erythema, pain associated with ulcers and also the reduction in recurrence of ulceration with no side-effects attributed to the drug. When compared with topical antiseptic, analgesic, and anesthetic agent (benzalkonium chloride 0.01%, choline salicylate 8.7% and lidocaine hydrochloride 2% paste. Hence topical amlexanox could be a treating modality for minor RAS and has tremendous scope for further research in management this intractable condition.
